Article
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes.
Nature metabolism - 1 Sept 2020
Cai Erica P, Ishikawa Yuki, Zhang Wei, Leite Nayara C, Li Jian, Hou Shurong, Kiaf Badr, Hollister-Lock Jennifer, Yilmaz Nese Kurt, Schiffer Celia A, Melton Douglas A, Kissler Stephan, Yi Peng
Abstract excerpt
Type 1 diabetes (T1D) is caused by the autoimmune destruction of pancreatic beta cells. Pluripotent stem cells can now be differentiated into beta cells, thus raising the prospect of a cell replacement therapy for T1D. However, autoimmunity would rapidly destroy newly transplanted beta cells. Using a genome-scale CRISPR screen in a mouse model for T1D, we show that deleting RNLS, a genome-wide association study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.